Microbot Medical (NASDAQ:MBOT) Stock Rating Upgraded by Wall Street Zen

Microbot Medical (NASDAQ:MBOT) was upgraded by research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

MBOT has been the subject of a number of other research reports. B. Riley Financial initiated coverage on shares of Microbot Medical in a report on Tuesday, February 10th. They issued a “buy” rating for the company. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Microbot Medical in a report on Tuesday, April 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Microbot Medical in a report on Friday, April 10th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Microbot Medical presently has a consensus rating of “Moderate Buy” and an average target price of $7.50.

Microbot Medical Stock Performance

NASDAQ MBOT opened at $1.85 on Friday. The company has a quick ratio of 21.93, a current ratio of 22.59 and a debt-to-equity ratio of 0.01. The firm has a market cap of $124.26 million, a PE ratio of -7.12 and a beta of 1.06. The company has a 50 day moving average price of $2.36 and a 200 day moving average price of $2.20. Microbot Medical has a 52 week low of $1.60 and a 52 week high of $4.67.

Microbot Medical (NASDAQ:MBOT) last posted its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.03. The firm had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.30 million. As a group, sell-side analysts forecast that Microbot Medical will post -0.34 EPS for the current fiscal year.

Institutional Trading of Microbot Medical

Large investors have recently made changes to their positions in the business. Cornerstone Advisory LLC purchased a new stake in shares of Microbot Medical in the 3rd quarter valued at $30,000. American Century Companies Inc. purchased a new stake in Microbot Medical during the second quarter worth $32,000. Zacks Investment Management purchased a new stake in Microbot Medical during the third quarter worth $33,000. Man Group plc purchased a new stake in Microbot Medical during the fourth quarter worth $35,000. Finally, Squarepoint Ops LLC purchased a new stake in Microbot Medical during the third quarter worth $37,000. 16.30% of the stock is owned by hedge funds and other institutional investors.

Microbot Medical Company Profile

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.